Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
34.60
-0.57 (-1.62%)
At close: Oct 31, 2025, 4:00 PM EDT
35.50
+0.90 (2.60%)
After-hours: Oct 31, 2025, 7:32 PM EDT
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $166.50M in the quarter ending June 30, 2025, with 13.24% growth. This brings the company's revenue in the last twelve months to $610.16M, up 26.77% year-over-year. In the year 2024, Ultragenyx Pharmaceutical had annual revenue of $560.23M with 29.01% growth.
Revenue (ttm)
$610.16M
Revenue Growth
+26.77%
P/S Ratio
5.47
Revenue / Employee
$471,529
Employees
1,294
Market Cap
3.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 560.23M | 125.98M | 29.01% |
| Dec 31, 2023 | 434.25M | 70.92M | 19.52% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
RARE News
- 5 days ago - Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 9 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - GlobeNewsWire
- 5 weeks ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 weeks ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 2 months ago - Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Ultragenyx to Participate at Investor Conferences in September - GlobeNewsWire